136.1 ð é«åžçç
136.1.0.1 ð äžé éé»
- åé¡:
- Acute hematogenous (å ç«¥ long bone metaphysis; æäºº vertebra) â S. aureus #1
- Contiguous (é°è¿ SSTI, post-op, trauma) â polymicrobial
- Diabetic foot â polymicrobial (Staph, Strep, Gram -, anaerobes)
- Vertebral (æäººæåžž osteo) â S. aureus; TB (Pottâs); Brucella
- Prosthetic / implant â biofilm: S. epidermidis (CoNS), S. aureus, P. aeruginosa
- 蚺æ·:
- MRI = gold (sensitivity 90%+); CT for bone fragments
- Bone culture (biopsy or aspirate) = essential â antibiotic ä¹å
- ESR, CRP ââ; WBC variable
- æ²»ç: 6 é± IV standard (Vanc + 3rd gen ceph) â de-escalate; surgery if abscess / dead bone / refractory
- 22E update: POET trial-like oral switch for stable osteomyelitis (OVIVA trial 2019, NEJM)
136.1.0.2 1ïžâ£ ç å by Context
| æ å¢ | äž»èŠç å |
|---|---|
| Adult community, hematogenous | S. aureus (MSSA + MRSA), GBS, GAS |
| Children long bone | S. aureus, K. kingae, S. pyogenes |
| Sickle cell | Salmonella (#1), S. aureus |
| IVDU | S. aureus, Pseudomonas (rare), Candida |
| DM foot | Polymicrobial: S. aureus, Strep, Enterobacteriaceae, anaerobes, Pseudomonas |
| Vertebral | S. aureus #1, GN (E. coli, Pseudomonas), TB, Brucella, fungi |
| Prosthetic joint / implant | CoNS (S. epidermidis), S. aureus, P. acnes (shoulder), Enterobacteriaceae |
| Post-puncture wound foot | Pseudomonas through sneaker (classic) |
136.1.0.3 2ïžâ£ èšåºè¡šçŸ
136.1.0.3.1 Acute Hematogenous (å ç«¥)
- æ¥æ§çŒçã骚çãè¢é« limping
- Long bone metaphysis (femur, tibia)
- ESR/CRP ââ
- MRI æ©èšº; bone scan alt
136.1.0.3.2 Vertebral Osteomyelitis (Adult, æåžžèŠæäººéªšé«ç)
- è人 / DM / éæ / IVDU
- Insidious back pain (weeks), low-grade fever (50%), neuro 猺倱 (compression)
- Imaging: MRI with contrast (sensitivity 95%+) â vertebral body + endplate + disc
- Source: hematogenous (UTI, IE, IV catheter); contiguous (epidural injection); IVDU
- Workup: blood cultures à 2, TB workup, CT-guided biopsy (if cultures negative)
- Treatment: 6-12 wks IV antibiotic per organism
- Surgical: epidural abscess + neuro deficit; spinal instability; refractory
136.1.0.4 3ïžâ£ æ²»ç
136.1.0.4.1 Empirical
- Vancomycin + Ceftriaxone (community, hematogenous)
- Vanco + Pip-tazo / Cefepime (DM foot, hospital, severe)
- Pediatric: Cefazolin (MSSA) or Vanco (MRSA) + Ceftriaxone
136.1.0.4.2 Specific Organism
| Organism | Treatment | Duration |
|---|---|---|
| MSSA | Cefazolin OR Nafcillin | 4-6 wks IV |
| MRSA | Vancomycin / Daptomycin / Linezolid | 4-6 wks |
| Strep | Penicillin / Ceftriaxone | 4-6 wks |
| Pseudomonas | Cefepime / Pip-tazo / Ceftolozane + aminoglycoside | 6 wks |
| Salmonella | Ceftriaxone | 4-6 wks (sickle cell) |
| TB (Pottâs) | RIPE Ã 2 mo + INH/RIF Ã 7-10 mo | 9-12 mo |
| Brucella | Doxy + Streptomycin or Rifampin | 6 wks |
| Fungal | Amphotericin B â azole | months |